Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Nature

Volumn 547, Issue 7662, 2017, Pages 222-226

  Sahin, Ugur ^a,b   Derhovanessian, Evelyna ^a   Miller, Matthias ^a   Kloke, Björn Philipp ^a   Simon, Petra ^a   Löwer, Martin ^b   Bukur, Valesca ^a,b   Tadmor, Arbel D ^b   Luxemburger, Ulrich ^a   Schrörs, Barbara ^b   Omokoko, Tana ^a   Vormehr, Mathias ^a,b   Albrecht, Christian ^b   Paruzynski, Anna ^a   Kuhn, Andreas N ^a   Buck, Janina ^a   Heesch, Sandra ^a   Schreeb, Katharina H ^a   Müller, Felicitas ^a   Ortseifer, Inga ^a   Vogler, Isabel ^a   Godehardt, Eva ^a   Attig, Sebastian ^b   Rae, Richard ^b   Breitkreuz, Andrea ^a   Tolliver, Claudia ^a   Suchan, Martin ^b   Martic, Goran ^b   Hohberger, Alexander ^b   Sorn, Patrick ^b   Diekmann, Jan ^a   Ciesla, Janko ^a   Waksmann, Olga ^a   Brück, Alexandra Kemmer ^a   Witt, Meike ^a   Zillgen, Martina ^a   Rothermel, Andree ^b   Kasemann, Barbara ^b   Langer, David ^a   Bolte, Stefanie ^a   Diken, Mustafa ^a,b   Kreiter, Sebastian ^a,b   Nemecek, Romina ^c   Gebhardt, Christoffer ^d,e   Grabbe, Stephan ^b   Höller, Christoph ^c   Utikal, Jochen ^d,e   Huber, Christoph ^a,b   Loquai, Carmen ^b   Türeci, Özlem ^f   more..

^a BIONTECH AG   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f German Cancer Research Center ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; HLA A ANTIGEN; HLA B ANTIGEN; MELANOMA VACCINE; RNA VACCINE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; CANCER VACCINE; CD274 PROTEIN, HUMAN; CD8 ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RNA;

CANCER; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; IMMUNE RESPONSE; IMMUNITY; MUTATION; PROTEIN; RNA; TUMOR; VACCINATION; VACCINE;

ADULT; AGED; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC LYMPHOCYTE; FEMALE; FIRST IN HUMAN STUDY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA CELL; METASTATIC MELANOMA; MIDDLE AGED; MULTICENTER STUDY; MUTATIONAL LOAD; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SANGER SEQUENCING; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; DEFICIENCY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METASTASIS; MUTATION; PREVENTION AND CONTROL; PROCEDURES; TUMOR RECURRENCE; VACCINATION;

ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; BETA 2-MICROGLOBULIN; CANCER VACCINES; CD8 ANTIGENS; EPITOPES; HUMANS; IMMUNOTHERAPY; MELANOMA; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PRECISION MEDICINE; PROGRAMMED CELL DEATH 1 RECEPTOR; RNA; T-LYMPHOCYTES; VACCINATION;

EID: 85024396858     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23003     Document Type: Article

References (42)

1. Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081-1091 (2012).
2. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
3. Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
4. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
5. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211 (2015).
6. McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463-1469 (2016).
7. Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255-2262 (2016).
8. Linnemann, C. et al. High-Throughput epitope discovery reveals frequent recognition of neo-Antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85 (2015).
9. Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400-404 (2012).
10. Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387-1390 (2015).
11. Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572-576 (2014).
12. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
13. Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808 (2015).
14. Delamarre, L., Mellman, I. & Yadav, M. Cancer immunotherapy. Neo approaches to cancer vaccines. Science 348, 760-761 (2015).
15. Kreiter, S. et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70, 9031-9040 (2010).
16. Bassani-Sternberg, M. et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).
17. Abelin, J. G. et al. Mass spectrometry profiling of HLA-Associated peptidomes in mono-Allelic cells enables more accurate epitope prediction. Immunity 46, 315-326 (2017).
18. Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancerimmune set point. Nature 541, 321-330 (2017).
19. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
20. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
21. DUrso, C. M. et al. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 87, 284-292 (1991).
22. Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819-829 (2016).
23. Melero, I. et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457-472 (2015).
24. Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
25. Dudley, M. E., Wunderlich, J. R., Shelton, T. E., Even, J. & Rosenberg, S. A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 26, 332-342 (2003).
26. Holtkamp, S. et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 108, 4009-4017 (2006).
27. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
28. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
29. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat. Methods 5, 621-628 (2008).
30. Kim, Y. et al. Immune epitope database analysis resource. Nucleic Acids Res. 40, W525-W530 (2012).
31. Untergasser, A. et al. Primer3-new capabilities and interfaces. Nucleic Acids Res. 40, e115 (2012).
32. Koressaar, T. & Remm, M. Enhancements and modifications of primer design program Primer3. Bioinformatics 23, 1289-1291 (2007).
33. Kent, W. J. BLAT-The BLAST-like alignment tool. Genome Res. 12, 656-664 (2002).
34. Kreiter, S. et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J. Immunol. 180, 309-318 (2008).
35. Grudzien-Nogalska, E. et al. Synthetic mRNAs with superior translation and stability properties. Methods Mol. Biol. 969, 55-72 (2013).
36. Kuhn, A. N. et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo. Gene Ther. 17, 961-971 (2010).
37. Berensmeier, S. Magnetic particles for the separation and purification of nucleic acids. Appl. Microbiol. Biotechnol. 73, 495-504 (2006).
38. Simon, P. et al. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes. Cancer Immunol. Res. 2, 1230-1244 (2014).
39. Brochet, X., Lefranc, M.-P. & Giudicelli, V. IMGT/V-QUEST: The highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503-W508 (2008).
40. Thorvaldsdóttir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178-192 (2013).
41. Zhao, Q.-Y. et al. Optimizing de novo transcriptome assembly from short-read RNA-Seq data: A comparative study. BMC Bioinformatics 12 (Suppl 14), S2 (2011).
42. Omokoko, T. A. et al. Luciferase mRNA transfection of antigen presenting cells permits sensitive nonradioactive measurement of cellular and humoral cytotoxicity. J. Immunol. Res. 2016, 9540975 (2016).